康莱特注射液联合化疗治疗中晚期非小细胞肺癌的文献及临床研究

发布时间：2019-03-02 21:08

【摘要】：目的:评价康莱特注射液联合化疗治疗中晚期非小细胞肺癌(NSCLC)的疗效和生活质量改善情况及不良反应。方法:论文一:根据Cochrane协作网系统评价方法,计算机检索中国学术期刊全文数据库(CNKI)、万方数据库,同时手工检索杂志刊登的相关文献,检索时间为2005年1月至2016年12月,全面收集符合标准的随机对照试验(RCT)。采取改良的Jadad量表评价文献质量,应用Rev Man5.3软件进行Meta分析,分析指标为计数资料,用比值比(OR)及其95%可信区间(95%CI)表示。论文二:收集2015年1月-2017年1月于辽宁中医肿瘤科住院的中晚期NSCLC患者41例,按照治疗方式不同分为2组,对照组予常规化疗方案,治疗组在此基础上予康莱特注射液200ml/d静点,21天为1疗程,共进行4个疗程。本研究采用SPSS21.0软件,进行卡方检验,以P0.05为有意义。结果:论文一:1.共收集相关文献343篇,其中纳入15个改良的Jadad量表评分3分以上的随机对照试验,共计1230例中晚期NSCLC患者。较对照组,康莱特联合化疗治疗NSCLC合并效应量(OR=2.62,95%CI:1.79-3.83,Z=4.97,P0.00001)。改善生活质量(OR=3.40,95%CI:2.51-4.60,Z=7.93,P0.00001)。减轻白细胞下降(OR=0.35,95%CI:0.24-0.50,Z=5.84,P0.00001)。降低胃肠道反应(OR=0.52,95%CI:0.33-0.82,Z=2.80,P=0.005)。各项指标较对照组差异均有统计学意义。论文二:2.回顾性分析得出康莱特试验组总有效率为68.18%,对照组为36.84%,对比有统计学差异(P0.05);对照组在骨髓抑制方面的效果与试验组近似,两者比较无统计学差异(P0.05)。而对照组在产生消化道不良反应方面较试验组严重,且差异有统计学意义(P0.05)。结论:1.康莱特注射液联合化疗在治疗有效率方面较单纯化疗显示出明显优势。2.康莱特注射液在改善化疗不良反应方面效果肯定。3.康莱特注射液是一种综合调整、疗效确切且安全的治疗中晚期NSCLC的中药制剂。
[Abstract]:Objective: to evaluate the efficacy and quality of life (QOL) of Kanglaite injection combined with chemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC). Methods: according to the systematic evaluation method of Cochrane collaborative network, we searched the (CNKI), Wanfang database of Chinese academic journal full-text database by computer, and searched the relevant literatures published in the journal by hand. The retrieval time was from January 2005 to December 2016. Comprehensive collection of standard randomized controlled trial (RCT). The improved Jadad scale was used to evaluate the literature quality. The Meta analysis was carried out by Rev Man5.3 software. The indexes were counted data and expressed by the ratio (OR) and its 95% confidence interval (95%CI). Thesis 2: 41 patients with advanced NSCLC hospitalized in Liaoning Cancer Department of traditional Chinese Medicine from January 2015 to January 2017 were divided into two groups according to the different treatment methods. The control group was given routine chemotherapy regimen, and the patients in the control group were divided into two groups according to the different treatment methods. On this basis, the treatment group was given Kanglaite injection 200ml/d intravenous point, 21 days as a course of treatment, a total of 4 courses. This research uses SPSS21.0 software, carries on the chi-square test, takes the P0.05 as the significance. Results: papers I: 1. A total of 343 literatures were collected, among which 15 randomized controlled trials with 3 or more scores were included in the modified Jadad scale. 1230 patients with advanced NSCLC were enrolled in this study. Compared with the control group, Kanglaite combined with chemotherapy in the treatment of NSCLC combined with response volume (OR=2.62,95%CI:1.79-3.83,Z=4.97,P0.00001). Improve the quality of life (OR=3.40,95%CI:2.51-4.60,Z=7.93,P0.00001). Reduce leukopenia (OR=0.35,95%CI:0.24-0.50,Z=5.84,P0.00001). Decrease gastrointestinal reaction (OR=0.52,95%CI:0.33-0.82,Z=2.80,P=0.005). Compared with the control group, all the indexes were significantly different from those in the control group. Thesis II: 2. Retrospective analysis showed that the total effective rate of Kanglaite test group was 68.18%, and that of control group was 36.84%, the difference was statistically significant (P0.05). The effect of myelosuppression in the control group was similar to that in the experimental group, but there was no significant difference between the two groups (P0.05). The side effects of digestive tract in the control group were more serious than those in the experimental group, and the difference was statistically significant (P0.05). Conclusions: 1. Kanglaite injection combined with chemotherapy showed obvious advantages over chemotherapy alone in the treatment of the effective rate. 2. The effect of Kanglaite injection in improving the side effects of chemotherapy is positive. 3. Kanglaite injection is a comprehensive adjustment, effective and safe Chinese medicine preparation for the treatment of advanced NSCLC.
【学位授予单位】：辽宁中医药大学
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R734.2

【参考文献】